Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing...
Clinical Trial
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual...
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
- Treatment with denifanstat achieved statistically significant and clinically meaningful improvements in disease activity, MASH resolution and fibrosis -- Results...
Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway
Realigning resources to focus on clinical advancement of Selected TIL therapyReducing employee headcount by approximately 60%Streamlining operations with cash runway...
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual...
FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Approval is based on Phase III INAVO120 results, showing the Itovebi™ (inavolisib)-based regimen more than doubled progression-free survival compared with...
NMPA Grants Marketing Approval to the First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China
GUANGZHOU, China, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), an...
Cantargia Reports New Positive Results on Biomarkers and Safety in CAN10 Phase 1 Clinical Study
LUND, SE / ACCESSWIRE / October 11, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced new...
Delegation of International Communication Experts and Foreign Media Outlets Visits Emerging Industry Enterprises in Zhongshan, Guangdong Province
BEIJING, Oct. 10, 2024 /PRNewswire/ -- On October 9, 2024, the delegation of international communication experts and foreign media outlets,...
ObvioHealth Announces the Appointment of Nicholas Campbell to Its Board of Directors
Seasoned Healthcare Executive Nicholas Campbell Joins ObvioHealth Board of Directorsto Drive Digital Innovation in Clinical Trials NEW YORK, Oct. 10,...
Microsoft expands AI capabilities to shape a healthier future
REDMOND, Wash., Oct. 10, 2024 /PRNewswire/ -- On Thursday, Microsoft Corp. is unveiling several Microsoft Cloud for Healthcare innovations that...
Dynocardia’s Direct Continuous Blood Pressure Monitoring Technology Receives Grant from NIH’s Commercialization Readiness Pilot Program
The grant, which is awarded to companies developing significantly impactful technologies with the potential to change clinical practice, will support...
Movano Health Provides Update on FDA Review of EvieMED Ring
The Company continues to work closely with the FDA to bring this pioneering healthcare product to market PLEASANTON, Calif., Oct....
Clario and PathAI Collaborate to Deliver Integrated Solution for GI Clinical Trials
Partnership combines revolutionary digital pathology and endoscopy solutions, enhancing drug development for IBD and other GI disorders Strategic Partnership: Streamlined, single-vendor...
International Myeloma Foundation Launches Clinical Trial Matching Engine in Partnership with SparkCures
SparkCures’ best-in-class clinical trial matching and navigation service is now accessible via myeloma.org.STUDIO CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE)...
Alpha Tau Treats First Patient with Recurrent Lung Cancer
JERUSALEM, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the...
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
DOYLESTOWN, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company...
Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program
Company’s VP of Education and Global Training Named Chairman of ASRM Corporate Member CouncilATLANTA, Oct. 10, 2024 (GLOBE NEWSWIRE) --...
Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)
– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical...
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
FDA approval for the IND submission to conduct its trial already secured Vancouver, Canada, Oct. 10, 2024 (GLOBE NEWSWIRE) --...